Eli Lilly Shares Jump 54% as Revenue Grows 56% and Margin Hits 47%
ABBV•Over nine months, Eli Lilly’s shares climbed 54%, boosting market value by over $200 billion to exceed $1 trillion. In its latest quarter, revenue rose 56% year-over-year with $12.8 billion in incretin sales and a 47.3% operating margin, while FDA approved oral weight-management pill Foundayo and Lilly agreed to acquire several clinical-stage biotechs.
1. Stock Repricing on Breakout Growth
Eli Lilly’s shares surged 54% over nine months, adding over $200 billion in market value and pushing the company past the $1 trillion valuation threshold. This dramatic rerating reflects investor confidence in sustained growth rather than a short-term bounce.
2. Incretin Franchise Drives Revenue and Profitability
In the latest quarter, Lilly achieved 56% year-over-year revenue growth, driven by $12.8 billion in sales of Mounjaro and Zepbound. The company converted this surge into a 47.3% operating margin, up from a three-year average of 35.3%, underscoring its efficiency in scaling blockbuster therapies.
3. Future Catalysts: Foundayo and Pipeline Expansion
Lilly secured FDA approval for Foundayo, the first oral incretin therapy for obesity, opening a new multi-billion-dollar market. To strengthen long-term prospects, Lilly inked deals to acquire clinical-stage biotechs including Orna Therapeutics and Centessa Pharmaceuticals, aiming to fuel the next wave of innovation.
